Nature of The Business - Additional Information (Details) $ in Thousands				3 Months Ended	12 Months Ended
	Jan. 26, 2023 USD ($)	Mar. 04, 2022 USD ($)	Jan. 28, 2022	Mar. 21, 2023 USD ($)	Dec. 31, 2022 USD ($) shares	Feb. 28, 2022 shares	Feb. 08, 2022 shares	Dec. 31, 2021 USD ($) shares	Jun. 30, 2021 shares
Class of Stock [Line Items]
Accumulated Deficit					$ (318,790)			$ (130,111)
Proceeds from issuance of private placement					9,958
Upfront payment received					325,000
Cash, cash equivalents and marketable securities					$ 254,800
Common stock, shares authorized | shares					1,000,000,000		1,000,000,000.0	185,000,000	185,000,000
Reverse stock split ratio			0.1817
Certificate of Incorporation
Class of Stock [Line Items]
Common stock, shares authorized | shares						1,000,000,000.0			185,000,000.0
Reverse stock split describtion					On January 28, 2022, the Company effected a one-for-5.5041 reverse stock split of its common stock and preferred stock in connection with its initial public offering (IPO) in February 2022.
Subsequent Event
Class of Stock [Line Items]
Proceeds from issuance of private placement and non-refundable upfront payment				$ 325,000
Subsequent Event | Kite Collaboration Agreement
Class of Stock [Line Items]
Non-refundable upfront payment received				225,000
Potential payments of clinical, regulatory and commercial milestones				3,900,000
IPO | Certificate of Incorporation
Class of Stock [Line Items]
Reverse stock split ratio			0.1817
Private Placement
Class of Stock [Line Items]
Proceeds from issuance of private placement		$ 10,000
Private Placement | Subsequent Event | Gilead Common Stock Purchase Agreement
Class of Stock [Line Items]
Proceeds from issuance of private placement	$ 100,000			$ 100,000